AU4412096A – Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
– Google Patents
AU4412096A – Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
– Google Patents
Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
Info
Publication number
AU4412096A
AU4412096A
AU44120/96A
AU4412096A
AU4412096A
AU 4412096 A
AU4412096 A
AU 4412096A
AU 44120/96 A
AU44120/96 A
AU 44120/96A
AU 4412096 A
AU4412096 A
AU 4412096A
AU 4412096 A
AU4412096 A
AU 4412096A
Authority
AU
Australia
Prior art keywords
reversal
reagent
induction
treatment
immune responses
Prior art date
1994-12-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU44120/96A
Inventor
Leonid Beigelman
Alex Burgin
Kenneth Draper
John Gustofson
Thale Jarvis
Alexander Karpeisky
Jasenka Matulic-Adamic
James Mcswiggen
Anil Modak
Pamela Pavco
Daniel T Stinchcomb
James D. Thompson
Nassim Usman
Francine Wincott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sirna Therapeutics Inc
Original Assignee
Ribozyme Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1994-12-13
Filing date
1995-11-22
Publication date
1996-07-03
1994-12-23
Priority claimed from US08/363,254
external-priority
patent/US5891684A/en
1994-12-23
Priority claimed from US08/363,253
external-priority
patent/US5891683A/en
1995-02-17
Priority claimed from US08/390,850
external-priority
patent/US5612215A/en
1995-04-20
Priority claimed from US08/426,124
external-priority
patent/US5716824A/en
1995-05-02
Priority claimed from US08/432,874
external-priority
patent/US5627053A/en
1995-08-07
Priority claimed from US08/512,861
external-priority
patent/US6146886A/en
1995-10-05
Priority claimed from US08/541,365
external-priority
patent/US5672501A/en
1995-11-22
Application filed by Ribozyme Pharmaceuticals Inc
filed
Critical
Ribozyme Pharmaceuticals Inc
1996-07-03
Publication of AU4412096A
publication
Critical
patent/AU4412096A/en
Status
Abandoned
legal-status
Critical
Current
Links
Espacenet
Global Dossier
Discuss
Classifications
C—CHEMISTRY; METALLURGY
C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
C12N15/09—Recombinant DNA-technology
C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
C07H19/06—Pyrimidine radicals
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
C07H19/06—Pyrimidine radicals
C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
C07H19/16—Purine radicals
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
C07H19/16—Purine radicals
C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
C—CHEMISTRY; METALLURGY
C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
C12N15/09—Recombinant DNA-technology
C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
C—CHEMISTRY; METALLURGY
C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
C12Y—ENZYMES
C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
C12Y304/24—Metalloendopeptidases (3.4.24)
C12Y304/24017—Stromelysin 1 (3.4.24.17)
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K38/00—Medicinal preparations containing peptides
C—CHEMISTRY; METALLURGY
C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
C12N2310/00—Structure or type of the nucleic acid
C12N2310/10—Type of nucleic acid
C12N2310/11—Antisense
C12N2310/111—Antisense spanning the whole gene, or a large part of it
C—CHEMISTRY; METALLURGY
C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
C12N2310/00—Structure or type of the nucleic acid
C12N2310/10—Type of nucleic acid
C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
C12N2310/121—Hammerhead
C—CHEMISTRY; METALLURGY
C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
C12N2310/00—Structure or type of the nucleic acid
C12N2310/30—Chemical structure
C12N2310/31—Chemical structure of the backbone
C12N2310/315—Phosphorothioates
C—CHEMISTRY; METALLURGY
C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
C12N2310/00—Structure or type of the nucleic acid
C12N2310/30—Chemical structure
C12N2310/32—Chemical structure of the sugar
C—CHEMISTRY; METALLURGY
C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
C12N2310/00—Structure or type of the nucleic acid
C12N2310/30—Chemical structure
C12N2310/32—Chemical structure of the sugar
C12N2310/321—2′-O-R Modification
C—CHEMISTRY; METALLURGY
C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
C12N2310/00—Structure or type of the nucleic acid
C12N2310/30—Chemical structure
C12N2310/32—Chemical structure of the sugar
C12N2310/322—2′-R Modification
C—CHEMISTRY; METALLURGY
C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
C12N2310/00—Structure or type of the nucleic acid
C12N2310/30—Chemical structure
C12N2310/33—Chemical structure of the base
C—CHEMISTRY; METALLURGY
C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
C12N2310/00—Structure or type of the nucleic acid
C12N2310/30—Chemical structure
C12N2310/33—Chemical structure of the base
C12N2310/332—Abasic residue
C—CHEMISTRY; METALLURGY
C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
C12N2310/00—Structure or type of the nucleic acid
C12N2310/30—Chemical structure
C12N2310/34—Spatial arrangement of the modifications
C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
AU44120/96A
1994-12-13
1995-11-22
Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
Abandoned
AU4412096A
(en)
Applications Claiming Priority (21)
Application Number
Priority Date
Filing Date
Title
US363253
1982-03-29
US363254
1982-04-01
US000974
1993-01-06
US35492094A
1994-12-13
1994-12-13
US354920
1994-12-13
US08/363,254
US5891684A
(en)
1992-10-15
1994-12-23
Base-modified enzymatic nucleic acid
US08/363,253
US5891683A
(en)
1993-09-02
1994-12-23
Non-nucleotide containing enzymatic nucleic acid
US390850
1995-02-17
US08/390,850
US5612215A
(en)
1992-12-07
1995-02-17
Stromelysin targeted ribozymes
US08/426,124
US5716824A
(en)
1995-04-20
1995-04-20
2′-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes)
US426124
1995-04-20
US432874
1995-05-02
US08/432,874
US5627053A
(en)
1994-03-29
1995-05-02
2’deoxy-2′-alkylnucleotide containing nucleic acid
US43450995A
1995-05-04
1995-05-04
US434509
1995-05-04
US000951
1995-07-07
US512861
1995-08-07
US08/512,861
US6146886A
(en)
1994-08-19
1995-08-07
RNA polymerase III-based expression of therapeutic RNAs
US541365
1995-10-05
US08/541,365
US5672501A
(en)
1994-12-23
1995-10-05
Base-modified enzymatic nucleic acid
PCT/US1995/015516
WO1996018736A2
(en)
1994-12-13
1995-11-22
Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
Publications (1)
Publication Number
Publication Date
AU4412096A
true
AU4412096A
(en)
1996-07-03
Family
ID=56289667
Family Applications (1)
Application Number
Title
Priority Date
Filing Date
AU44120/96A
Abandoned
AU4412096A
(en)
1994-12-13
1995-11-22
Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
Country Status (3)
Country
Link
AU
(1)
AU4412096A
(en)
CA
(1)
CA2207593A1
(en)
WO
(1)
WO1996018736A2
(en)
Families Citing this family (76)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
EP1484067A3
(en)
1995-02-08
2005-03-02
Takara Bio Inc.
Cancer control
US5807743A
(en)
*
1996-12-03
1998-09-15
Ribozyme Pharmaceuticals, Inc.
Interleukin-2 receptor gamma-chain ribozymes
ATE342911T1
(en)
*
1996-12-24
2006-11-15
Sirna Therapeutics Inc
SYNTHESIS OF NUCLEOSIDES AND POLYNUCLEOTIDES
US6248878B1
(en)
1996-12-24
2001-06-19
Ribozyme Pharmaceuticals, Inc.
Nucleoside analogs
US6319906B1
(en)
*
1996-12-31
2001-11-20
Isis Pharmaceuticals
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
WO1998050530A2
(en)
*
1997-05-09
1998-11-12
Ribozyme Pharmaceuticals, Inc.
Enzymatic nucleic acids: synthesis, selection and use
US6280936B1
(en)
1997-06-09
2001-08-28
Ribozyme Pharmaceuticals, Inc.
Method for screening nucleic acid catalysts
US6548657B1
(en)
1997-06-09
2003-04-15
Ribozyme Pharmaceuticals, Inc.
Method for screening nucleic acid catalysts
US6183959B1
(en)
1997-07-03
2001-02-06
Ribozyme Pharmaceuticals, Inc.
Method for target site selection and discovery
US6316612B1
(en)
1997-08-22
2001-11-13
Ribozyme Pharmaceuticals, Inc.
Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides
US6656731B1
(en)
1997-09-22
2003-12-02
Max Planck Gesellschaft Zur Forderung Der Wissenschaften E.V.
Nucleic acid catalysts with endonuclease activity
US6127173A
(en)
*
1997-09-22
2000-10-03
Ribozyme Pharmaceuticals, Inc.
Nucleic acid catalysts with endonuclease activity
US6127535A
(en)
1997-11-05
2000-10-03
Ribozyme Pharmaceuticals, Inc.
Nucleoside triphosphates and their incorporation into oligonucleotides
US6617438B1
(en)
1997-11-05
2003-09-09
Sirna Therapeutics, Inc.
Oligoribonucleotides with enzymatic activity
AU3751299A
(en)
1998-04-20
1999-11-08
Ribozyme Pharmaceuticals, Inc.
Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
WO1999055857A2
(en)
*
1998-04-29
1999-11-04
Ribozyme Pharmaceuticals, Inc.
Nucleoside triphosphates and their incorporation into ribozymes
EP1493818A3
(en)
*
1998-04-29
2006-02-15
Ribozyme Pharmaceuticals, Inc.
Nucleoside triphosphates and their incorporation into ribozymes
EP2221311B1
(en)
*
1999-07-15
2013-08-21
TAGCyx Biotechnologies
Novel nucleic acid base pair
US6831171B2
(en)
2000-02-08
2004-12-14
Yale University
Nucleic acid catalysts with endonuclease activity
US7125660B2
(en)
2000-09-13
2006-10-24
Archemix Corp.
Nucleic acid sensor molecules and methods of using same
US20050148530A1
(en)
2002-02-20
2005-07-07
Sirna Therapeutics, Inc.
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US9994853B2
(en)
2001-05-18
2018-06-12
Sirna Therapeutics, Inc.
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20050043256A1
(en)
2001-07-30
2005-02-24
Isis Pharmaceuticals, Inc.
Antisense modulation of stearoyl-CoA desaturase expression
US7132529B2
(en)
*
2001-07-30
2006-11-07
Isis Pharmaceuticals, Inc.
Antisense modulation of stearoyl-CoA desaturase expression
US9181551B2
(en)
2002-02-20
2015-11-10
Sirna Therapeutics, Inc.
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2
(en)
2002-02-20
2017-05-23
Sirna Therapeutics, Inc.
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003207708A1
(en)
2002-02-20
2003-09-09
Sirna Therapeutics, Inc.
Rna interference mediated inhibition of map kinase genes
AU2012216354B2
(en)
*
2002-08-05
2016-01-14
Silence Therapeutics Gmbh
Further novel forms of interfering RNA molecules
DK1527176T4
(en)
2002-08-05
2017-07-03
Silence Therapeutics Gmbh
ADDITIONAL NEW FORMS OF INTERFERRING RNA MOLECULES
US7829694B2
(en)
2002-11-26
2010-11-09
Medtronic, Inc.
Treatment of neurodegenerative disease through intracranial delivery of siRNA
US7605249B2
(en)
2002-11-26
2009-10-20
Medtronic, Inc.
Treatment of neurodegenerative disease through intracranial delivery of siRNA
US7618948B2
(en)
2002-11-26
2009-11-17
Medtronic, Inc.
Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA
US7732591B2
(en)
2003-11-25
2010-06-08
Medtronic, Inc.
Compositions, devices and methods for treatment of huntington’s disease through intracranial delivery of sirna
US7994149B2
(en)
2003-02-03
2011-08-09
Medtronic, Inc.
Method for treatment of Huntington’s disease through intracranial delivery of sirna
US7897582B2
(en)
2003-05-23
2011-03-01
Isis Pharmaceuticals, Inc.
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US7960355B2
(en)
2003-05-23
2011-06-14
Isis Pharmaceuticals, Inc.
Compositions and methods for the modulation of the expression of B7 protein
EP1704250B1
(en)
2003-12-31
2012-09-19
The Penn State Research Foundation
Methods for predicting and overcoming resistance to chemotherapy in ovarian cancer
US10508277B2
(en)
2004-05-24
2019-12-17
Sirna Therapeutics, Inc.
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
ATE501252T1
(en)
2004-06-22
2011-03-15
Univ Illinois
METHOD FOR INHIBITING TUMOR CELL GROWTH USING FOXM1 SIRNS
EP1897878A4
(en)
*
2005-06-24
2009-05-06
Yamasa Corp
Stable crystal of protected pseudouridine
US9133517B2
(en)
2005-06-28
2015-09-15
Medtronics, Inc.
Methods and sequences to preferentially suppress expression of mutated huntingtin
ES2937245T3
(en)
2005-08-23
2023-03-27
Univ Pennsylvania
RNA containing modified nucleosides and methods of using the same
CN101321775B
(en)
2005-10-03
2012-05-23
大学健康网络
ODCASE inhibitors for the treatment of malaria
DK1981902T3
(en)
2006-01-27
2015-10-05
Biogen Ma Inc
Nogo Receptor Antagonists
US7741469B2
(en)
2006-04-05
2010-06-22
University Of Iowa Research Foundation
Compositions for treating hearing loss and methods of use thereof
US9273356B2
(en)
2006-05-24
2016-03-01
Medtronic, Inc.
Methods and kits for linking polymorphic sequences to expanded repeat mutations
JP2010500011A
(en)
2006-08-08
2010-01-07
ガンサー ハートマン
Structure and use of 5 ‘phosphate oligonucleotides
US9375440B2
(en)
2006-11-03
2016-06-28
Medtronic, Inc.
Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
EP2297323A1
(en)
2008-05-21
2011-03-23
Hartmann, Gunther
5′ triphosphate oligonucleotide with blunt end and uses thereof
EP2408458A1
(en)
2009-03-19
2012-01-25
Merck Sharp&Dohme Corp.
RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012520685A
(en)
2009-03-19
2012-09-10
メルク・シャープ・エンド・ドーム・コーポレイション
RNA interference-mediated inhibition of GATA binding protein 3 (GATA3) gene expression using small interfering nucleic acids (siNA)
US20120016011A1
(en)
2009-03-19
2012-01-19
Merck Sharp & Dohme Corp.
RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA)
CN102439151A
(en)
2009-03-19
2012-05-02
默沙东公司
Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach 1) gene expression using short interfering nucleic acid (sina) sequence listing
WO2010111471A2
(en)
2009-03-27
2010-09-30
Merck Sharp & Dohme Corp.
RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111490A2
(en)
2009-03-27
2010-09-30
Merck Sharp & Dohme Corp.
RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2411516A1
(en)
2009-03-27
2012-02-01
Merck Sharp&Dohme Corp.
RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111468A2
(en)
2009-03-27
2010-09-30
Merck Sharp & Dohme Corp.
RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
EP2411517A2
(en)
2009-03-27
2012-02-01
Merck Sharp&Dohme Corp.
RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US9420770B2
(en)
2009-12-01
2016-08-23
Indiana University Research & Technology Corporation
Methods of modulating thrombocytopenia and modified transgenic pigs
US8710209B2
(en)
2009-12-09
2014-04-29
Nitto Denko Corporation
Modulation of HSP47 expression
CA2800065A1
(en)
2010-05-21
2011-11-24
Peptimed, Inc.
Reagents and methods for treating cancer
SG186438A1
(en)
2010-06-24
2013-01-30
Quark Pharmaceuticals Inc
Double stranded rna compounds to rhoa and use thereof
EP3330377A1
(en)
2010-08-02
2018-06-06
Sirna Therapeutics, Inc.
Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
RU2624045C2
(en)
2010-08-17
2017-06-30
Сирна Терапьютикс,Инк
RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP3372684B1
(en)
2010-08-24
2020-10-07
Sirna Therapeutics, Inc.
Single-stranded rnai agents containing an internal, non-nucleic acid spacer
US9233997B2
(en)
2010-08-26
2016-01-12
Sirna Therapeutics, Inc.
RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA)
DK2632472T3
(en)
2010-10-29
2018-03-19
Sirna Therapeutics Inc
RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
SG190088A1
(en)
2010-11-01
2013-06-28
Peptimed Inc
Compositions of a peptide targeting system for treating cancer
EP2681314B1
(en)
2011-03-03
2017-11-01
Quark Pharmaceuticals, Inc.
Compositions and methods for treating lung disease and injury
EP2508530A1
(en)
2011-03-28
2012-10-10
Rheinische Friedrich-Wilhelms-Universität Bonn
Purification of triphosphorylated oligonucleotides using capture tags
US10196637B2
(en)
2011-06-08
2019-02-05
Nitto Denko Corporation
Retinoid-lipid drug carrier
TWI658830B
(en)
2011-06-08
2019-05-11
日東電工股份有限公司
Retinoid-liposomes for enhancing modulation of hsp47 expression
AU2013208012A1
(en)
2012-01-12
2014-07-03
Quark Pharmaceuticals, Inc.
Combination therapy for treating hearing and balance disorders
DK2895608T3
(en)
2012-09-12
2019-01-21
Quark Pharmaceuticals Inc
DOUBLE-STRENGTHED OIGONUCLEOTIDE MOLECULES FOR P53 AND PROCEDURES FOR USING IT
EP2712870A1
(en)
2012-09-27
2014-04-02
Rheinische Friedrich-Wilhelms-Universität Bonn
Novel RIG-I ligands and methods for producing them
WO2023097308A1
(en)
2021-11-29
2023-06-01
Hongene Biotech Corporation
Synthesis of 2’ acetyl-ester protected nucleosides
Family Cites Families (8)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
ATE271064T1
(en)
*
1990-01-11
2004-07-15
Isis Pharmaceuticals Inc
OLIGONUCLEOTIDE DERIVATIVES FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION
DE4216134A1
(en)
*
1991-06-20
1992-12-24
Europ Lab Molekularbiolog
SYNTHETIC CATALYTIC OLIGONUCLEOTIDE STRUCTURES
WO1993023569A1
(en)
*
1992-05-11
1993-11-25
Ribozyme Pharmaceuticals, Inc.
Method and reagent for inhibiting viral replication
CA2140343A1
(en)
*
1992-07-17
1994-02-03
Sean M. Sullivan
Method and reagent for treatment of animal diseases
WO1995004818A1
(en)
*
1993-08-06
1995-02-16
Ribozyme Pharmaceuticals, Inc.
Method and reagent for inhibiting human immunodeficiency virus replication
CA2176035A1
(en)
*
1993-11-08
1995-05-18
Nassim Usman
Base-modified enzymatic nucleic acid
WO1995013380A2
(en)
*
1993-11-12
1995-05-18
Ribozyme Pharmaceuticals, Inc.
Method and reagent for treatment of arthritic conditions
WO1995023225A2
(en)
*
1994-02-23
1995-08-31
Ribozyme Pharmaceuticals, Inc.
Method and reagent for inhibiting the expression of disease related genes
1995
1995-11-22
WO
PCT/US1995/015516
patent/WO1996018736A2/en
not_active
Application Discontinuation
1995-11-22
AU
AU44120/96A
patent/AU4412096A/en
not_active
Abandoned
1995-11-22
CA
CA002207593A
patent/CA2207593A1/en
not_active
Abandoned
Also Published As
Publication number
Publication date
WO1996018736A3
(en)
1996-09-19
WO1996018736A2
(en)
1996-06-20
CA2207593A1
(en)
1996-06-20
Similar Documents
Publication
Publication Date
Title
AU4412096A
(en)
1996-07-03
Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
AU4372296A
(en)
1996-06-19
Passive transfer immune serum and method of making
GB2288257B
(en)
1998-09-30
Improved nutritional micromcomputer and method
AUPM957194A0
(en)
1994-12-15
Wastewater treatment method and plant
AU3687897A
(en)
1998-03-12
Food processing method and system
AU1875692A
(en)
1992-12-21
Exhaust treatment system and method
AU6527294A
(en)
1994-10-24
Solid-tumor treatment method
AU2469795A
(en)
1995-11-29
Liquid treatment method and system
AU3550995A
(en)
1996-04-09
Field prioritization apparatus and method
AU4549896A
(en)
1996-08-21
High-vacuum oil refinery system and process
AU5426196A
(en)
1996-10-08
Apparatus and method for blood analyses
EP0677807A3
(en)
1996-10-23
Processing system and method of operation.
AU2168395A
(en)
1995-12-21
Wastewater treatment method and apparatus
GB2287807B
(en)
1998-05-06
Join processing system and method
AU4244796A
(en)
1996-06-19
Delaminating method and apparatus
AU3724697A
(en)
1998-02-09
Methods of treating milk products
PL314893A1
(en)
1996-12-23
Sewage treatment system and method
AU5573398A
(en)
1998-08-18
Peritoneal dialysis apparatus and method
EP0616116A3
(en)
1994-12-21
Induction system and method of operating an engine.
AU3574395A
(en)
1996-04-26
Magnetic treatment of fluids
AU5100996A
(en)
1996-09-23
Method and device for treating foodstuffs
AUPM885294A0
(en)
1994-11-10
Chemically assisted protein annealing treatment
AU8761198A
(en)
1999-03-01
Apparatus and method for magnetically treating milk products
EP0675152A3
(en)
1996-10-09
Organosilicon polymers and method of preparation.
AU4425497A
(en)
1998-04-14
Method and apparatus for processing clinical trial databases
None